An E-value-Informed Sensitivity Analysis Framework for Hybrid Controlled Trials.

Hybrid controlled trials (HCTs) incorporate real-world data into randomized controlled trials (RCTs) by augmenting the internal control arm with patients receiving the same treatment in routine care. Beyond increasing power, HCTs may improve recruitment by supporting unequal randomization ratios that increase patient access to experimental treatments. However, HCT validity is threatened by bias from unmeasured confounding due to lack of randomization of external controls, leading to outcome non-exchangeability between internal and external control patients. To address this challenge, we developed a sensitivity analysis framework to assess the robustness of HCT results to potential unmeasured confounding. We propose a tipping point analysis that adapts the E-value framework to the HCT setting where trial participation rather than treatment assignment is subject to confounding. To aid interpretation, we also introduce a data-driven benchmark representing the strength of unmeasured confounding reflected by the observed outcome non-exchangeability. We then propose an operational decision rule and evaluate its performance through simulation studies. Finally, we illustrate the approach using an asthma trial augmented by data from electronic health records. Simulation results demonstrate that our decision rule safeguards against Type I error inflation while preserving the power gains achieved by incorporating external data. In settings where moderate unmeasured confounding led to poorer outcomes for external controls, Type I error was controlled near the nominal 5% level, and power increased by 10-20% compared with analyses using RCT data alone. Our approach provides a practical, interpretable method to assess HCT robustness, supporting rigorous inference when integrating external real-world data.